Lexaria’s DehydraTECH-Nicotine Faster than ZYN and on!
KELOWNA, BC / ACCESSWIRE / August 9, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to report results from…
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to report its intention to…
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned…
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
KELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has been granted a strategically…
Lexaria Biotech: An Undervalued Growth Opportunity
Last month, we highlighted Lexaria Bioscience Corp. (Nasdaq: LEXX) as a biotech company that was trading at a discount and wanted to issue an update after it made several important…
Lexaria Receives New Patents
KELOWNA, BC / ACCESSWIRE / June 20, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that it has received notifications of…
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
KELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce additional findings from…
Lexaria Bioscience Continues To Execute
Last week, Lexaria Bioscience Corp. (Nasdaq: LEXX) reported two major developments that our readers should be aware of. The more significant announcement was Lexaria awarding a contract for clinical research…
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
KELOWNA, BC / ACCESSWIRE / April 24, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has awarded the contract for…
Lexaria Biosciences: An Undervalued Biotech Opportunity
When analyzing biotech companies, positive clinical trial results are the most significant potential catalyst for businesses. For this reason, we are favorable on companies that have been reporting positive results…
